Construction and transfection of a ribozyme targeting human caspase-3

Deirdre Cronin1, Carmel Daly, Toni O'Doherty

  • 1National Institute for Cellular Biotechnology, Dublin City University, Glasnevin, Dublin 9, Ireland.

Anticancer Research
|May 22, 2004
PubMed

Insights

Researchers designed a ribozyme to target human caspase-3, a protein crucial for apoptosis. This ribozyme effectively reduced caspase-3 mRNA and protein in lung cancer cells, demonstrating its potential for gene regulation.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Research

Background:

  • Caspase-3 is a critical enzyme in apoptosis (programmed cell death).
  • Targeting caspase-3 is a potential strategy for cancer therapy.
  • Drug-resistant cancer cell lines present a challenge in treatment.

Purpose of the Study:

  • To design and validate a ribozyme targeting human caspase-3.
  • To assess the efficacy of the ribozyme in down-regulating caspase-3 expression in a lung carcinoma cell line.

Main Methods:

  • In vitro cleavage assays to test ribozyme activity.
  • Transfection of a ribozyme into a drug-resistant human lung carcinoma cell line (DLKP-A5F).
  • Analysis of caspase-3 mRNA and protein levels following stable and transient transfection.

Main Results:

  • The designed ribozyme demonstrated effective in vitro cleavage activity.
  • Successful down-regulation of human caspase-3 mRNA was achieved.
  • Significant reduction in human caspase-3 protein levels was observed in transfected cells.

Conclusions:

  • A novel ribozyme effectively targets and reduces human caspase-3 expression.
  • This ribozyme shows potential as a tool for modulating apoptosis in cancer cells.
  • The findings support the use of ribozymes for gene silencing in drug-resistant cancer models.